- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04574960
Neoadjuvant øvre traktat invasiv kreftforsøk (NAUTISK) (NAUTICAL)
Neoadjuvant kjemoterapi i øvre del av urinrørskreft: En multisenter, gjennomførbarhetspilotforsøk
Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the tube that drains the kidney). This type of cancer is rare and as a result, there are only a few studies that have looked at it.
Standard of care for UTUC would be surgery followed by chemotherapy (adjuvant chemotherapy). However, we know from studies that have looked at cancer of the lining of the bladder, which is a similar cancer in many ways, that treating people with chemotherapy before surgery (neoadjuvant chemotherapy) can lead to longer survival compared to the standard of care. There are no studies to show this in UTUC. Neoadjuvant chemotherapy is thought to help improve survival by treating any cancer that may have spread from the original tumour but that is not visible yet on scans. This study would be the first clinical trial in Canada to evaluate the use of chemotherapy before surgery in this disease setting.
Since UTUC is rare, the purpose of this study is to determine if it is possible to enrol enough patients to a trial looking at the use of chemotherapy before surgery.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Emily Hickey
- Telefonnummer: (416) 270-5395
- E-post: emily.hickey@uhn.ca
Studiesteder
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H8L6
- Rekruttering
- The Ottawa Hospital
-
Ta kontakt med:
- Pascale Juneau
- Telefonnummer: 73852 613-737-8899
- E-post: pjuneau@ohri.ca
-
Hovedetterforsker:
- Rodney Breau, MD
-
Toronto, Ontario, Canada, M5G2M9
- Rekruttering
- University Health Network
-
Ta kontakt med:
- Sarah Cheung
- Telefonnummer: (437) 335-2949
- E-post: sarah.cheung@uhn.ca
-
Hovedetterforsker:
- Girish Kulkarni, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Newly diagnosed radiographically visible (CT or MRI) cT1-4 N0 M0 with positive selective urinary cytology, positive bladder urinary cytology, or endoscopic biopsy for high grade urothelial cell carcinoma
- Age ≥18 years of age
- Eastern Cooperative Oncology Group (ECOG) score 0-1
- Medically appropriate candidate for radical nephroureterectomy or ureterectomy as per participating site attending urologic oncologist
- Medically appropriate candidate for cisplatin-based chemotherapy as per participating site attending medical oncologist
- Adequate organ system function defined as follows: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,00/mm3, hemoglobin ≥ 90 g/L, ALT and AST < 2.5 x upper limit of normal, electrolytes (Na, K, Mg, Ca): within normal limits, GFR ≥ 60 mL/min
Patients who are randomized to the adjuvant chemotherapy will be reassessed for suitability to receive adjuvant chemotherapy after definitive surgery (nephroureterectomy or ureterectomy) based on the following criteria:
- pT2-4 N0-3 M0 or pT any N1-3 M0 with predominant urothelial component
- ECOG score 0-2
- Medically appropriate candidate for platin-based chemotherapy as per participating site attending medical oncologist
- Adequate organ system function defined as follows: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,00/mm3, hemoglobin ≥ 90 g/L, ALT and AST < 2.5 x upper limit of normal, electrolytes (Na, K, Mg, Ca): within normal limits, GFR ≥ 30 mL/min
Exclusion Criteria:
- Metastatic disease
- Radiographically visible nodal disease
- Concurrent muscle-invasive bladder cancer (non-muscle invasive bladder cancer is acceptable)
- Solitary kidney
- Other cancer diagnosis or systemic chemotherapy use within 2 years of study enrollment (prior bladder cancer and intravesical therapy allowed)
- Concomitant diseases that are a formal exclusion to cisplatin chemotherapy (deafness, ≥ grade II neuropathy, serious active infection)
- Concomitant use of any other investigational drugs
- Pregnancy or breast feeding (you must remain on contraception, not father a child or donate sperm while receiving gemcitabine/cisplatin and for 6 months following the last dose)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Neoadjuvant Chemotherapy Arm
Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. This will be followed by surgical intervention (nephroureterectomy or ureterectomy). |
Gemcitabine 1000 mg/m^2, IV infusion on days 1 and 8 of each 3-week cycle
Andre navn:
Cisplatin 70 mg/m^2, IV infusion on day 1 of each 3-week cycle
Andre navn:
|
|
Aktiv komparator: Adjuvant Chemotherapy Arm (Standard of Care)
Patients will undergo surgical intervention (nephroureterectomy or ureterectomy) followed by adjuvant chemotherapy. Patients with a GFR greater or equal to 60 mL/min will receive Gemcitabine/Cisplatin while those with a GFR greater or equal to 30 mL/min but less than 60 mL/min will receive Gemcitabine/Carboplatin. Gemcitabine/Cisplatin will be administered on a 3-week cycle for up to 4 cycles. Gemcitabine/Carboplatin will be administered on a 3-week cycle for up to 4 cycles. |
Gemcitabine 1000 mg/m^2, IV infusion on days 1 and 8 of each 3-week cycle
Andre navn:
Cisplatin 70 mg/m^2, IV infusion on day 1 of each 3-week cycle
Andre navn:
Carboplatin AUC 5-6 calculated using the Calvert formula on day 1 of each cycle
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mulighet for å inkludere cT1-4N0 M0 UTUC-pasienter i en randomisert studie av neoadjuvant kjemoterapi versus standardbehandling ved å vurdere rekrutteringsrater for pilotforsøk
Tidsramme: 24 måneder
|
24 måneder
|
|
|
Disease-free survival (DFS)
Tidsramme: 36 months
|
DFS is defined as the time from randomization to development of intravesical recurrence, contralateral upper tract recurrence or distant metastasis |
36 months
|
|
Rate of complete pathologic response
Tidsramme: 36 months
|
Complete pathologic response is defined as pT0 N0 |
36 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Nettstedsspesifikk påmeldingsrate
Tidsramme: 24 måneder
|
24 måneder
|
|
Antall pasienter oppsøkt per sted per måned
Tidsramme: 24 måneder
|
24 måneder
|
|
Antall pasienter randomisert per sted per måned
Tidsramme: 24 måneder
|
24 måneder
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Girish Kulkarni, MD, University Health Network - Princess Margaret Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Urologiske neoplasmer
- Urinblæresykdommer
- Neoplasmer i urinblæren
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinasjonskomplekser
- Deoxycytidine
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Platinumforbindelser
- Gemcitabin
- Karboplatin
- Cisplatin
Andre studie-ID-numre
- 20-5149
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .